Skip to main content

Evidence-Based Supplement Research

Evidence-Based Supplement Research

N-Acetyl Cysteine and Reduced Tumor Necrosis Factor Alpha

Doses used in studies

mg/day: 2,400 (median 2,400, IQR 2,400–2,400) — 1 study

Time to effect

Median: 6.1 months · IQR 6.1 months–6.1 months · Range 6.1 months–6.1 months — Reported in 1 of 2 studies

Safety in these studies

Overall tolerabilityReported
Group 2 has substantial improvement in various metabolic parameters and health-related quality of life with accepted safety profile parameters.
from: New Approach Combination-Dosed Therapy for Nonalcoholic Steatohepatitis Versus Vitamin E:

2 of 2 papersPopulation:

New Approach Combination-Dosed Therapy for Nonalcoholic Steatohepatitis Versus Vitamin E: A Randomized Controlled Trial.
- 2025-08
- RCT · n = 45
- Clinical therapeutics 47(8)
- - Amr Y Zakaria
  - Rehab Badawi
  - Hasnaa Osama
  - Mona A Abdelrahman
  - Asmaa M El-Kalaawy
- PubMed: 40480879
- DOI: 10.1016/j.clinthera.2025.05.006
13 Insights on
- Reduced Tumor Necrosis Factor Alpha
- High evidence
- Clinical
Group 2 exhibited substantial reductions in mean levels of all biological markers: ... tumor necrosis factor-α by 9.64% (P < 0.05)
Effect
Beneficial
Effect size
Small
Significant
Yes
Dose
1200 mg twice daily
N-Acetyl-L-cysteine in human rheumatoid arthritis and its effects on nitric oxide (NO) and malondialdehyde (MDA): analytical and clinical considerations.
- 2022-07-13
- Review
- Amino acids 54(9)
- - Dimitrios Tsikas
  - Marie Mikuteit
- PubMed: 35829920
- DOI: 10.1007/s00726-022-03185-x
5 Insights on
- Reduced Tumor Necrosis Factor Alpha
- Low evidence
Reported data on NO, MDA and clinical parameters, including C-reactive protein, interleukins and tumour necrosis factor α, are contradictory in the literature.
Effect
Neutral
Effect size
Small
Significant
No